Pharmanutra SpA (PHNU)

Currency in EUR
65.70
-1.50(-2.23%)
Closed·
PHNU is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
65.2067.10
52 wk Range
38.7568.10
Key Statistics
Prev. Close
67.2
Open
67.1
Day's Range
65.2-67.1
52 wk Range
38.75-68.1
Volume
12.13K
Average Volume (3m)
21.9K
1-Year Change
20.9945%
Book Value / Share
6.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHNU Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
82.33
Upside
+25.32%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 5 consecutive years

Pharmanutra SpA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Pharmanutra SpA Company Profile

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It also offers iron deficiency, inflammation, mineral and vitamin, muscle and joint, sports nutrition, ophthalmic, and night rest products; and medical instrumentation and software for body bioimpedance analysis. The company sells its products through sales representatives, wholesalers, pharmacies, para-pharmacies, agents, distributors, online sales, local partners, and tenders. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

Employees
136
Market
Italy

Compare PHNU to Peers and Sector

Metrics to compare
PHNU
Peers
Sector
Relationship
P/E Ratio
37.0x18.6x12.4x
PEG Ratio
4.71−0.010.03
Price/Book
9.8x2.5x1.5x
Price / LTM Sales
5.1x1.4x0.9x
Upside (Analyst Target)
26.5%6.5%16.4%
Fair Value Upside
Unlock16.3%9.9%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 82.33
(+25.32% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.82%
Dividend Yield
1.49%
Industry Median 2.14%
Annualised payout
1.00
Paid annually
5-Years Growth
+16.80%
Growth Streak

Earnings

Latest Release
Nov 10, 2025
EPS / Forecast
0.50 / --
Revenue / Forecast
32.65M / --
EPS Revisions
Last 90 days

PHNU Income Statement

People Also Watch

8.524
BMPS
-0.40%
3.172
NEXII
+0.03%
3.4970
SPMI
+1.24%
98.0800
PRY
-3.37%
6.421
STLAM
-4.21%

FAQ

What Is the Pharmanutra (PHNU) Stock Price Today?

The Pharmanutra stock price today is 65.70 EUR.

What Stock Exchange Does Pharmanutra Trade On?

Pharmanutra is listed and trades on the Milan Stock Exchange.

What Is the Stock Symbol for Pharmanutra?

The stock symbol for Pharmanutra is "PHNU."

What Is the Pharmanutra Market Cap?

As of today, Pharmanutra market cap is 628.05M EUR.

What Is Pharmanutra's Earnings Per Share (TTM)?

The Pharmanutra EPS (TTM) is 1.82.

When Is the Next Pharmanutra Earnings Date?

Pharmanutra will release its next earnings report on Mar 17, 2026.

From a Technical Analysis Perspective, Is PHNU a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Pharmanutra Stock Split?

Pharmanutra has split 0 times.

How Many Employees Does Pharmanutra Have?

Pharmanutra has 136 employees.

What is the current trading status of Pharmanutra (PHNU)?

As of Feb 19, 2026, Pharmanutra (PHNU) is trading at a price of 65.70 EUR, with a previous close of 67.20 EUR. The stock has fluctuated within a day range of 65.20 EUR to 67.10 EUR, while its 52-week range spans from 38.75 EUR to 68.10 EUR.

What Is Pharmanutra (PHNU) Price Target According to Analysts?

The average 12-month price target for Pharmanutra is 82.33 EUR, with a high estimate of 88 EUR and a low estimate of 74 EUR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +25.32% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.